España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Johnson & Johnson
JNJ
NYSE
Watchlist
Get Report
Perks
Buy
Compare Brokers
$145.93
0.24
0.16%
Last update: 3:24 PM
15 minutes delayed
Get Report
Watch
Q2 2024 Earnings in 12 days from now on Wed Jul 17th, before the market open
Johnson & Johnson (JNJ) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Johnson & Johnson (NYSE:JNJ) Stock
Johnson & Johnson Stock (NYSE: JNJ)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, July 05, 2024
"Toxic Arsenic And Lead Commonly Found In Tam...
Benzinga Newsdesk
What's Going On With Johnson and Johnson Shares Friday?
Dylan Berman
Wednesday, July 03, 2024
Health Canada Authorizes RYBREVANT In Combina...
Benzinga Newsdesk
Tuesday, July 02, 2024
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Vandana Singh
Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
Vandana Singh
Johnson & Johnson's Second Interim Analysis O...
Benzinga Newsdesk
Monday, July 01, 2024
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Chris Katje
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry
Benzinga Insights
Judge Blocks Cancer Victims' Attempt To Stop Johnson & Johnson Bankruptcy Plan
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on Jo...
Benzinga Newsdesk
Friday, June 28, 2024
Johnson & Johnson Shares Results From The Nip...
Benzinga Newsdesk
J&J Says CHMP Adopts Positive Opinion For Bal...
Benzinga Newsdesk
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Avi Kapoor
CHMP Adopted Positive Opinion For Janssen 's...
Benzinga Newsdesk
Reported Earlier, Supreme Court Blocks Purdue...
Benzinga Newsdesk
Thursday, June 27, 2024
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
Vandana Singh
Wednesday, June 26, 2024
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Vandana Singh
Tuesday, June 25, 2024
Cantor Fitzgerald Reiterates Overweight on Jo...
Benzinga Newsdesk
Monday, June 24, 2024
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
Vandana Singh
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
Benzinga Insights
Friday, June 21, 2024
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Zacks
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Vandana Singh
Thursday, June 20, 2024
Johnson & Johnson Submits Application To FDA ...
Benzinga Newsdesk
Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products
Vandana Singh
Johnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on Jo...
Benzinga Newsdesk
Tuesday, June 18, 2024
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
Surbhi Jain
Monday, June 17, 2024
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Priya Nigam
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Vandana Singh
Market Analysis: Johnson & Johnson And Competitors In Pharmaceuticals Industry
Benzinga Insights
In-Depth Examination Of 11 Analyst Recommendations For Johnson & Johnson
Benzinga Insights
RBC Capital Reiterates Outperform on Johnson ...
Benzinga Newsdesk
Johnson & Johnson Submits An FDA Application ...
Benzinga Newsdesk
Reported Saturday, Johnson & Johnson's Phase ...
Benzinga Newsdesk
Friday, June 14, 2024
J&J Reports Updated Phase 2 CAPTIVATE Study R...
Benzinga Newsdesk
FDA On June 13 Updates Advice To Manufacturer...
Benzinga Newsdesk
Johnson & Jonson Reports Long-term Data From ...
Benzinga Newsdesk
Thursday, June 13, 2024
How Is The Market Feeling About Johnson & Johnson?
Benzinga Insights
Xencor Has Been Notified Janssen Will Termina...
Benzinga Newsdesk
Wednesday, June 12, 2024
Ovarian Cancer Victims File Motion To Halt Jo...
Benzinga Newsdesk
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor
Johnson & Johnson To Pay $700M To Settle Multi-State Talc Investigation
Benzinga Neuro
Tuesday, June 11, 2024
Johnson & Johnson Reaches $700M Settlement Wi...
Benzinga Newsdesk
New York Attorney General Files Lawsuit Again...
Benzinga Newsdesk
Friday, June 07, 2024
FDA Advised Manufacturers Of Authorized Covid...
Benzinga Newsdesk
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Vandana Singh
Johnson & Johnson MedTech's DePuy Synthes Rec...
Benzinga Newsdesk
Thursday, June 06, 2024
Halozyme's ENHANZE Product Gets New Patent Grant in EU
Zacks
Wednesday, June 05, 2024
Novavax Says FDA Panel Backs Update For Monov...
Benzinga Newsdesk
FDA Advisers Support Inclusion Of JN1 COVID V...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch